Evaluation of new markers for minimal residual disease monitoring in B-cell precursor acute lymphoblastic leukemia: CD73 and CD86 are the most relevant new markers to increase the efficacy of MRD 2016; 00B: 000-000-Reference-Cited by-同舟云学术

Evaluation of new markers for minimal residual disease monitoring in B-cell precursor acute lymphoblastic leukemia: CD73 and CD86 are the most relevant new markers to increase the efficacy of MRD 2016; 00B: 000-000

Published:2016-10-27 Issue:1 Volume:94 Page:100-111
ISSN:1552-4949
Container-title:Cytometry Part B: Clinical Cytometry
language:en
Short-container-title:Cytometry

Author:

Tembhare Prashant R.¹,Ghogale Sitaram¹,Ghatwai Nisha¹,Badrinath Yajamanam¹,Kunder Nikesh¹,Patkar Nikhil V.¹,Bibi Asma R.¹,Chatterjee Gaurav¹,Arora Brijesh²,Narula Gaurav²,Banawali Shripad²,Deshpande Nilesh¹,Amare Prathibha³,Gujral Sumeet¹,Subramanian Papagudi G.¹

Affiliation:

1. Hematopathology Laboratory; Tata Memorial Center, Mumbai; Room 727, Hematopathology Laboratory, Annexe Building, 7th Floor, Tata Memorial Hospital, Parel 400012 Mumbai India

2. Department of Pediatric Oncology; Tata Memorial Center; Main Building, Ground floor, Tata Memorial Hospital, Parel 400012 Mumbai India

3. Department of Cancer Cytogenetics; Tata Memorial Center, Mumbaim; Room 726, Annexe Building, 7th Floor, Tata Memorial Hospital, Parel 400012 Mumbai India

Publisher

Wiley

Subject

Cell Biology,Histology,Pathology and Forensic Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/cyto.b.21486/fullpdf

Reference42 articles.

1. Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia;Coustan-Smith;Blood,2000

2. Minimal residual disease diagnostics in acute lymphoblastic leukemia: need for sensitive, fast, and standardized technologies;Dongen;Blood,2015

3. Minimal disseminated disease in childhood T-cell lymphoblastic lymphoma: A report from the children's oncology group;Coustan-Smith;J Clin Oncol,2009

4. Minimal residual disease tests provide an independent predictor of clinical outcome in adult acute lymphoblastic leukemia;Mortuza;J Clin Oncol,2002

5. Minimal residual disease after induction is the strongest predictor of prognosis in intermediate risk relapsed acute lymphoblastic leukaemia-Long-term results of trial ALL-REZ BFM P95/96;Eckert;Eur J Cancer,2013

Cited by 52 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunophenotypic Characteristics and Cytogenetic Analysis of Adolescent and Young Adult B-Cell Acute Lymphoblastic Leukemia: Correlations With Clinicopathological Parameters;Cureus;2024-09-05

2. Faster clinical decisions in B‐cell acute lymphoblastic leukaemia: A single flow cytometric 12‐colour tube improves diagnosis and minimal residual disease follow‐up;British Journal of Haematology;2024-03-03

3. Deciphering stage 0 hematogones by flow cytometry in follow‐up bone marrow samples of pediatric B—Acute lymphoblastic leukemia cases: A potential mimicker of residual disease after anti CD19 therapy;Cytometry Part B: Clinical Cytometry;2024-01-19

4. Glycosylation as regulator of human B-cell leukaemias in bone marrow;Frontiers in Hematology;2023-11-16

5. Updates on lymphoblastic leukemia/lymphoma classification and minimal/measurable residual disease analysis;Seminars in Diagnostic Pathology;2023-11